JP2022527646A5 - - Google Patents
Info
- Publication number
- JP2022527646A5 JP2022527646A5 JP2021560416A JP2021560416A JP2022527646A5 JP 2022527646 A5 JP2022527646 A5 JP 2022527646A5 JP 2021560416 A JP2021560416 A JP 2021560416A JP 2021560416 A JP2021560416 A JP 2021560416A JP 2022527646 A5 JP2022527646 A5 JP 2022527646A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- progression
- disease
- reduce
- inhibit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025060435A JP2025096316A (ja) | 2019-04-05 | 2025-04-01 | 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962830139P | 2019-04-05 | 2019-04-05 | |
| US62/830,139 | 2019-04-05 | ||
| PCT/US2020/026721 WO2020206354A1 (en) | 2019-04-05 | 2020-04-03 | Methods of depleting disease causing agents via antibody targeted phagocytosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025060435A Division JP2025096316A (ja) | 2019-04-05 | 2025-04-01 | 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022527646A JP2022527646A (ja) | 2022-06-02 |
| JP2022527646A5 true JP2022527646A5 (enExample) | 2023-04-06 |
Family
ID=72667025
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560416A Withdrawn JP2022527646A (ja) | 2019-04-05 | 2020-04-03 | 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法 |
| JP2025060435A Pending JP2025096316A (ja) | 2019-04-05 | 2025-04-01 | 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025060435A Pending JP2025096316A (ja) | 2019-04-05 | 2025-04-01 | 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20220169737A1 (enExample) |
| EP (1) | EP3947467A4 (enExample) |
| JP (2) | JP2022527646A (enExample) |
| KR (1) | KR20220031995A (enExample) |
| CN (1) | CN114502585A (enExample) |
| AU (1) | AU2020253621A1 (enExample) |
| BR (1) | BR112021019950A2 (enExample) |
| CA (1) | CA3136272A1 (enExample) |
| IL (1) | IL286967A (enExample) |
| MX (1) | MX2021012035A (enExample) |
| SG (1) | SG11202110663UA (enExample) |
| WO (1) | WO2020206354A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102590454B1 (ko) | 2016-07-07 | 2023-10-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| WO2021222894A1 (en) | 2020-05-01 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Anti-dectin-2 antibodies |
| MX2023004054A (es) | 2020-10-07 | 2023-06-29 | Dren Bio Inc | Anticuerpos anti-dectina 1 y metodos de uso de los mismos. |
| CN119301156A (zh) * | 2022-04-04 | 2025-01-10 | 德伦生物公司 | 抗Dectin-1抗体和其使用方法 |
| US20250223364A1 (en) * | 2022-04-04 | 2025-07-10 | Dren Bio, Inc. | Multispecific binding proteins that bind dectin-1 and cd20 and methods of use thereof |
| KR20260048578A (ko) * | 2023-07-31 | 2026-04-10 | 드렌 바이오 매니지먼트, 인크. | Dectin-1 및 TROP-2에 결합하는 다중특이적 결합 단백질 및 이의 사용 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101679949B (zh) * | 2007-02-23 | 2015-08-19 | 贝勒研究院 | 通过dectin-1激活人抗原呈递细胞的治疗性应用 |
| WO2012129227A1 (en) * | 2011-03-22 | 2012-09-27 | Baylor Research Institute | Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine |
| WO2018176159A1 (en) * | 2017-03-31 | 2018-10-04 | Zymeworks Inc. | Tumor antigen presentation inducer constructs and uses thereof |
| US12384850B2 (en) * | 2017-06-25 | 2025-08-12 | Systimmune, Inc. | Guidance and navigation control proteins and method of making and using thereof |
| CA3106796A1 (en) * | 2018-07-19 | 2020-01-23 | Oncohost Ltd | Il-31 improves efficacy of macrophage-based adoptive cell therapy for cancer |
| EA202190183A1 (ru) * | 2018-07-27 | 2021-05-18 | Алектор Ллс | Антитела к siglec-5 и способы их применения |
-
2020
- 2020-04-03 WO PCT/US2020/026721 patent/WO2020206354A1/en not_active Ceased
- 2020-04-03 EP EP20784394.7A patent/EP3947467A4/en active Pending
- 2020-04-03 BR BR112021019950A patent/BR112021019950A2/pt unknown
- 2020-04-03 CA CA3136272A patent/CA3136272A1/en active Pending
- 2020-04-03 MX MX2021012035A patent/MX2021012035A/es unknown
- 2020-04-03 CN CN202080038435.9A patent/CN114502585A/zh active Pending
- 2020-04-03 KR KR1020217036237A patent/KR20220031995A/ko active Pending
- 2020-04-03 AU AU2020253621A patent/AU2020253621A1/en active Pending
- 2020-04-03 JP JP2021560416A patent/JP2022527646A/ja not_active Withdrawn
- 2020-04-03 SG SG11202110663UA patent/SG11202110663UA/en unknown
- 2020-04-03 US US17/601,359 patent/US20220169737A1/en not_active Abandoned
-
2021
- 2021-10-04 IL IL286967A patent/IL286967A/en unknown
-
2024
- 2024-12-10 US US18/975,761 patent/US20250206826A1/en active Pending
-
2025
- 2025-04-01 JP JP2025060435A patent/JP2025096316A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7572146B2 (ja) | グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法 | |
| JP2020513791A5 (enExample) | ||
| JP2020007318A5 (enExample) | ||
| JP2021514973A5 (enExample) | ||
| WO2006121852A3 (en) | Anti-cd19 antibody therapy for autoimmune disease | |
| JP2011207882A5 (enExample) | ||
| JP2017500057A5 (enExample) | ||
| JP2015503909A5 (enExample) | ||
| WO2006089133A8 (en) | Anti-cd19 antibodies and uses in oncology | |
| JP2018500014A5 (enExample) | ||
| JP2014511179A5 (enExample) | ||
| CA3018341A1 (en) | Methods for reducing toxicity of a chemotherapeutic drug | |
| JP2013227339A5 (enExample) | ||
| US9273126B2 (en) | Humanized antibodies against the beta-amyloid peptide | |
| JP2013518903A5 (enExample) | ||
| JP2014529610A5 (enExample) | ||
| JP2023540526A5 (enExample) | ||
| JP2023540444A5 (enExample) | ||
| JP2021511387A5 (enExample) | ||
| JP2014533357A5 (enExample) | ||
| JP2017507131A5 (enExample) | ||
| JP2022500455A5 (enExample) | ||
| IL274007B1 (en) | Anti-CD3 antibody and pharmaceutical preparation containing it for the treatment of cancer | |
| JP2021529776A5 (enExample) | ||
| JP2019508382A5 (enExample) |